Related Experiment Videos
Primary angioplasty: the past, the present and the future
1Apollo Hospitals, Chennai, India.
Insights
Primary angioplasty (PTCA) offers benefits for acute myocardial infarction but requires skilled performance in suitable labs. It is a viable alternative to thrombolysis, especially for specific patient groups.
Area of Science:
- Cardiology
- Interventional Cardiology
Background:
- Primary percutaneous coronary intervention (PTCA) for acute myocardial infarction (AMI) has theoretical advantages.
- These benefits, including improved antegrade flow and reduced intracranial hemorrhage, have not consistently translated from trials to community practice.
Purpose of the Study:
- To evaluate the effectiveness and applicability of primary PTCA in the management of acute myocardial infarction.
- To identify patient subgroups and settings where primary PTCA is most beneficial.
Main Methods:
- Review of randomized trials and clinical data on primary angioplasty in acute myocardial infarction.
- Analysis of outcomes in sophisticated centers versus community settings.
- Assessment of PTCA in specific patient populations, including those with cardiogenic shock or contraindications to thrombolysis.
Main Results:
- Primary PTCA shows promise but its success in community settings is variable.
- Timely and skilled performance in appropriate laboratory settings is crucial for successful outcomes.
- PTCA is recommended for patients with cardiogenic shock and those unable to receive thrombolytic therapy.
Conclusions:
- Primary PTCA is a suitable alternative to thrombolytic therapy for acute myocardial infarction when performed correctly and timely.
- Future reperfusion strategies may involve a combination of thrombolytics, glycoprotein IIb/IIIa inhibitors, and primary angioplasty.
Abstract:
Primary angioplasty (PTCA) in acute myocardial infarction has many theoretical advantages including better antegrade flow and reduced intracranial haemorrhage. However the improvement in the mortality and morbidity of primary angioplasty in the randomized trials from sophisticated centres has not been translated to the community setting. Primary PTCA is a suitable alternative to thrombolytic therapy if performed in a timely fashion by persons skilled in the procedure in a suitable laboratory. It is also recommended in patients with cardiogenic shock and in those with contraindications to thrombolytic therapy. Combination of thrombolytics and glycoprotein IIb/IIIa inhibitors with primary angioplasty may form the reperfusion strategy of the future.